AstraZeneca’s Japanese subsidiary, AstraZeneca KK, signed a Master Clinical Study Agreement with Keio University School of Medicine based in Tokyo. The university reported that due to Japan’s slow pace of drug research, it has taken steps to build up its own clinical trial capabilities and improve the efficiency of its research.

AstraZeneca and Keio University will collaborate on future studies and support the development of new compounds within the school.